Merz Pharmaceuticals, LLC
Raleigh, NC
- UEI
- UMD1NK9KU143
- CAGE
- 71FU4
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 6601 Six Forks Rd #430, Raleigh, NC 27615, USA
- Website
- merzusa.com
- Founded
- 1953
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Consumer Discretionary
- Consumer Durables & Apparel
- Consumer Goods
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $946,449 |
| FY2025 | $143,561 |
| FY2024 | $653,990 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Veterans Affairs | $946,449 |
Contract vehicles
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Levodopa | Veterans Integrated Service Network 15 (VHA) | $236,612 | |
| Levodopa | Veterans Integrated Service Network 15 (VHA) | $709,836 | |
| Levodopa 42MG inhl cap 60 | Veterans Integrated Service Network 15 (VHA) | $143,561 | |
| Levodopa NDC 10144-0342-60 | Veterans Integrated Service Network 15 (VHA) | $653,990 | |
| Merz prolaryn GEL for tamc, hawaii. | Medical Command (Army) | $15,000 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Chartwell RX LLC | Congers, NY | 325412 Pharmaceutical Preparation Manufacturing |
| Mckesson Drug Company | — | 325412 Pharmaceutical Preparation Manufacturing |
| Exelan Pharmaceuticals Inc. | Boca Raton, FL | 325412 Pharmaceutical Preparation Manufacturing |
| Catalyst Pharmaceuticals, Inc. | Coral Gables, FL | 325412 Pharmaceutical Preparation Manufacturing |
| Amneal Pharmaceuticals Of New York, LLC | Medford, NY | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Merz Pharmaceuticals, LLC, a foreign-owned for-profit pharmaceutical company based in Raleigh, North Carolina, supplies specialized pharmaceutical products to the Department of Veterans Affairs and the Defense Health Agency as a prime contractor operating on the GSA Federal Supply Schedule for Pharmaceuticals and Drugs (FSS-61-IB), with no small-business set-aside designation across its federal footprint.
Merz Pharmaceuticals holds a single-award Blanket Purchase Agreement with the National Acquisition Center under GSA FSS-61-IB with a $12.057 million ceiling running through March 12, 2027, established March 13, 2025, for supply of Ampyra (dalfampridine) and Inbrijia (tirzepatide). The vendor's federal work concentrates almost entirely on Veterans Health Administration procurement. Veterans Integrated Service Network 12 accounts for 100% of award count (6 awards, $97.5 million combined potential value) across delivery orders for Levodopa pharmaceutical products under the same GSA Pharmaceuticals and Drugs schedule. Recent delivery orders include a $709,836.48 order placed March 9, 2026, for Levodopa supply (completion March 20, 2026); a $653,990.40 order placed September 25, 2024, for Levodopa NDC 10144-0342-60 (completion October 9, 2024); and a $236,612.16 order placed September 8, 2026, for Levodopa supply (completion September 22, 2026). The National Acquisition Center placed one award valued at $12.1 million for the Ampyra and Inbrijia BPA. The Defense Health Agency accounts for the remaining award, valued at $15 thousand.
All eight prime awards operate under the Pharmaceuticals and Drugs GSA schedule vehicle. Combined potential value across all awards stands at $109.6 million, though only $1.8 million (2% of potential value) has been obligated to date, reflecting the nature of GSA schedule procurement where ceiling values are stated but invoiced activity runs lower. Award frequency has been sporadic — two awards in 2019, one in 2021, one in 2024, two in 2025, and two in 2026 — with no consistent annual cadence. Merz Pharmaceuticals operates exclusively as a prime contractor with no recorded subcontract footprint.
Quick answers
Is Merz Pharmaceuticals, LLC registered in SAM.gov?
Yes. Merz Pharmaceuticals, LLC's SAM.gov registration is active through June 18, 2027.
What is Merz Pharmaceuticals, LLC's CAGE code?
Merz Pharmaceuticals, LLC's CAGE code is 71FU4, and its Unique Entity ID (UEI) is UMD1NK9KU143.
Which contract vehicles does Merz Pharmaceuticals, LLC hold?
Merz Pharmaceuticals, LLC holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has Merz Pharmaceuticals, LLC received in federal contracts?
Federal contracts obligated $143,561 to Merz Pharmaceuticals, LLC in fiscal year 2025 and $1,744,000 in fiscal years 2023 through 2027.
What is Merz Pharmaceuticals, LLC's most recent federal award?
Merz Pharmaceuticals, LLC's most recent federal contract award is Levodopa (36C77026N0048), from Veterans Integrated Service Network 15 (VHA), on September 8, 2026.
On GovTribe
See Merz Pharmaceuticals, LLC's full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors